Jessica Rehmel - Concepedia

Author

Jessica Rehmel

Also Known As

Jessica F. Rehmel, Jessica Fayer Rehmel, Jessica L. F. Rehmel, Jessica L. Fayer Rehmel, Jessica L. Rehmel, Jessica L.F. Rehmel, Jessica R. F. Rehmel, Jessica Rehmel

Publications

485

Citations

H-Index

Concepts

All Affiliations

Eli Lilly (United States)Covance (United States)

About

Jessica Rehmel is an author at Eli Lilly (United States) specializing in drug discovery, medicine, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	3	3	78
2	Biochemistry	2	2	57
3	Engineering	1	1	28
4	Biostatistics	1	1	28
5	Metabolism	1	1	29

Jessica Rehmel

Publications

464

Citations

H-Index

Page 1

	Year	Citations
INTERACTIONS OF TWO MAJOR METABOLITES OF PRASUGREL, A THIENOPYRIDINE ANTIPLATELET AGENT, WITH THE CYTOCHROMES P450 Jessica Rehmel, James A. Eckstein, Nagy A. Farid, Drug Metabolism and Disposition	2006	263
Disposition and Metabolism of LY2452473, a Selective Androgen Receptor Modulator, in Humans Ping Yi, Jessica Rehmel, Kenneth C. Cassidy, Drug Metabolism and Disposition	2012	40
Physiologically‐Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid‐to‐Lactone Conversion Bridget L. Morse, Jeffrey J. Alberts, Maria M. Posada, CPT Pharmacometrics & Systems Pharmacology Lactone FormPharmacokinetic ModelingBiochemistryPharmacological StudyAcid‐to‐lactone Conversion	2019	29
Current Practices, Gap Analysis, and Proposed Workflows for PBPK Modeling of Cytochrome P450 Induction: An Industry Perspective Niresh Hariparsad, Diane Ramsden, Kunal S. Taskar, Clinical Pharmacology & Therapeutics EngineeringGap AnalysisMolecular BiologyPhysiologically-based Pharmacokinetic ModelingBioanalysis	2021	28
Abstract CT153: Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors Palaniappan Kulanthaivel, Daruka Mahadevan, P. Kellie Turner, Cancer Research Breast OncologyHealthy SubjectsPharmacotherapySystem PharmacologyPre-clinical Pharmacology	2016	21
Investigational Small-Molecule Drug Selectively Suppresses Constitutive CYP2B6 Activity at the Gene Transcription Level: Physiologically Based Pharmacokinetic Model Assessment of Clinical Drug Interaction Risk Maciej J. Zamek‐Gliszczynski, Michael A. Mohutsky, Jessica Rehmel, Drug Metabolism and Disposition	2014	20
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer P. Kellie Turner, Stephen D. Hall, Sonya C. Chapman, Drug Metabolism and Disposition	2020	19
CYP‐mediated drug–drug interactions with evacetrapib, an investigational CETP inhibitor: <i>in vitro</i> prediction and clinical outcome Ellen A. Cannady, Jeffrey G. Suico, Ming‐Dauh Wang, British Journal of Clinical Pharmacology	2015	12
Disposition and metabolism of LY2603618, a Chk-1 inhibitor following intravenous administration in patients with advanced and/or metastatic solid tumors Enaksha Wickremsinhe, Scott M. Hynes, Margo D. Palmieri, Xenobiotica	2014	11
Disposition and metabolism of [<sup>14</sup>C]-galunisertib, a TGF-<b>β</b>RI kinase/ALK5 inhibitor, following oral administration in healthy subjects and mechanistic prediction of the effect of itraconazole on galunisertib pharmacokinetics Kenneth C. Cassidy, Ivelina Gueorguieva, Colin Miles, Xenobiotica	2017	11

Page 1